Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
about
New immunological approaches in treating and diagnosing CNS diseasesPlasma biomarkers of brain atrophy in Alzheimer's diseaseCurrent and future uses of neuroimaging for cognitively impaired patients.Voxel-based morphometry in Alzheimer's disease.Inhibition of beta-amyloid(1-40) Peptide Aggregation and Neurotoxicity by CitrateEarly intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing.Omega-3 fatty acids and cognitive function in women.Assessment of cognition in mild cognitive impairment: a comparative studySingle-nucleotide polymorphisms are associated with cognitive decline at Alzheimer's disease conversion within mild cognitive impairment patients.Quantitative structural MRI for early detection of Alzheimer's disease.Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects.Controversies in Alzheimer's disease drug developmentSodium MR imaging detection of mild Alzheimer disease: preliminary studyStructural imaging in early pre-states of dementia.Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications.Integrating ADNI results into Alzheimer's disease drug development programs.Boosting power for clinical trials using classifiers based on multiple biomarkers.Gray and white matter changes in subjective cognitive impairment, amnestic mild cognitive impairment and Alzheimer's disease: a voxel-based analysis studyPersonality and cognitive decline in the Baltimore Epidemiologic Catchment Area follow-up studyMulti-method analysis of MRI images in early diagnostics of Alzheimer's diseaseA peptide that binds specifically to the β-amyloid of Alzheimer's disease: selection and assessment of anti-β-amyloid neurotoxic effects.Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.Development of a magnetic immunosorbent for on-chip preconcentration of amyloid β isoforms: Representatives of Alzheimer's disease biomarkersAssessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.Early diagnosis of Alzheimer's disease: is MCI too late?Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study.Personality and risk for Alzheimer's disease in adults 72 years of age and older: a 6-year follow-up.Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.Amnestic mild cognitive impairment and early Alzheimer's disease in an asian memory clinic - evidence for a clinical spectrumUsing biomarkers to improve detection of Alzheimer's disease.For debate: substituting placebo controls in long-term Alzheimer's prevention trials.Preclinical AD Workgroup staging: pathological correlates and potential challenges.Alzheimer's disease: pathological mechanisms and recent insights.Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients.A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease.
P2860
Q26865204-BC2C5EBF-248A-4D1E-BB5E-A94A97D05DAFQ28741028-9E36A3EB-861A-4C76-ADFC-4604AD383AA1Q31143267-B80D1FD5-68DB-4059-BF7D-710C2BB42B44Q33382837-F6237DEA-DF89-4B1E-86AF-C690E9B0B3F4Q33514614-8B871B6D-9CAC-4080-A679-71081A6B32DFQ33656133-8786FFA2-1B0D-437C-83D2-B2E06121747FQ33677382-8D45EB0C-8C5D-4577-8546-F708C851E938Q33703851-3C98089B-B9F6-4C93-9A55-A8DA187C5168Q33714700-2566F973-FCC8-4042-839F-0D5F682E61DCQ33729033-79F92D83-701A-4B78-B383-D1B74FE82F8FQ33757934-F28C4584-C6D3-47D9-9050-F8D3DC033403Q33759397-8DEC4E3B-D7B1-4150-BB62-85A6D5532F94Q33805090-5C9636F6-67A4-455A-8968-2F6D4E7B37B3Q33836441-036B5A02-8889-46C6-818D-7F7CB5998E0DQ33967561-F844F0E7-65D9-4683-9378-EAF10C5C50A5Q33968419-B8B87F40-E818-44C7-A4FE-0EBBB1D3D243Q33987409-5DB2F7EA-93CF-4BAF-B434-922453D45E3BQ33990250-F372F30A-4526-4B53-BFC0-B42CA9742697Q34005078-2CBC9C47-0E35-4EFE-B699-69B1602E70CAQ34036972-0D68E054-B693-49AB-B352-25DD750B8903Q34055598-49D91EAD-0990-4DFB-A475-5B10CC043AF1Q34079353-9CEF3720-0A89-41F8-8329-D141E4CE4DFCQ34176310-4AEADE25-A52D-4DF0-8E2D-E5BADA39726FQ34308649-B5192857-E0EB-41B6-9FA3-8D9B8B4BE94FQ34318022-4D212C16-761D-46FD-8ACB-A65F3573A698Q34462406-7E7C8980-68EE-4760-A5D1-0C745D0DA9CBQ34991223-6BC3AAE1-7BB4-4F3A-8E24-E64462ABE8DEQ34992855-F69BF8B5-AB28-4F92-9CB6-D581E73AA000Q35029099-A1635F2F-D895-4403-A058-A91A4A030F76Q35046344-940343E6-0D1E-4C27-A60F-EDB72B5FCBEFQ35135672-7BD4398A-7557-4FE2-BEBD-C69678C35249Q35428425-6C2DA85E-3E57-494F-BD24-644D8AA89040Q35533115-D3FA2FB1-6106-4FBC-8977-1FB2B1187E46Q35579221-FD276904-E2B3-454A-A9F9-5716A668C818Q35633470-2C8CAE1B-F050-4F33-B28E-D40595BEA19AQ35687044-028CE75E-7A98-4D83-8788-312FCB079902Q35723110-2F614C88-AD92-4CC9-9DA2-BCFFD25DE96CQ35879102-14CCE2C9-D993-41BA-905B-25BC7C4D2AC7Q35940409-259D61C3-36D5-4F58-899A-5D3E8CEC51D4Q36007975-7F65003B-69DD-4D90-81FF-DFA7E7182E0F
P2860
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@ast
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@en
type
label
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@ast
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@en
prefLabel
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@ast
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@en
P1433
P1476
Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
@en
P2093
Christopher Clark
Rachelle Doody
P304
P356
10.1212/01.WNL.0000295996.54210.69
P407
P577
2007-10-01T00:00:00Z